Fatty acid synthase causes drug resistance by inhibiting TNF-α and ceramide production

Journal of Lipid Research

Volumn 54, Issue 3, 2013, Pages 776-785

  Liu, Hailan ^a   Wu, Xi ^a   Dong, Zizheng ^a   Luo, Zhiyong ^a   Zhao, Zhenwen ^a   Xu, Yan ^a,b   Zhang, Jian Ting ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Doxorubicin; Neutral sphingomyelinase; NK kappa B; Tumor necrosis factor

Indexed keywords

CASPASE 8; CERAMIDE; CISPLATIN; DITHIOTHREITOL; DOXORUBICIN; ETOPOSIDE; FATTY ACID SYNTHASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOXANTRONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROTEIN KINASE B; SPHINGOMYELIN PHOSPHODIESTERASE; TUMOR NECROSIS FACTOR ALPHA; VERAPAMIL; VINBLASTINE;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME SYNTHESIS; GAMMA IRRADIATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN FUNCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CERAMIDES; DOXORUBICIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY ACID SYNTHASES; HUMANS; NF-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84874027191     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M033811     Document Type: Article

References (45)

1. Liu, H., J. Y. Liu, X. Wu, and J. T. Zhang. 2010. Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker. Int. J. Biochem. Mol. Biol. 1 : 69-89.
2. Gao, Y., L. P. Lin, C. H. Zhu, Y. Chen, Y. T. Hou, and J. Ding. 2006. Growth arrest induced by C75, a fatty acid synthase inhibitor, was partially modulated by p38 MAPK but not by p53 in human hepatocellular carcinoma. Cancer Biol. Ther. 5 : 978-985.
3. Knowles, L. M., F. Axelrod, C. D. Browne, and J. W. Smith. 2004. A fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2. J. Biol. Chem. 279 : 30540-30545.
4. Li, J. N., M. Gorospe, F. J. Chrest, T. S. Kumaravel, M. K. Evans, W. F. Han, and E. S. Pizer. 2001. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res. 61 : 1493-1499.
5. Morikawa, K., C. Ikeda, M. Nonaka, and I. Suzuki. 2007. Growth arrest and apoptosis induced by quercetin is not linked to adipogenic conversion of human preadipocytes. Metabolism. 56 : 1656-1665.
6. Vazquez-Martin, A., R. Colomer, J. Brunet, R. Lupu, and J. A. Menendez. 2008. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif. 41 : 59-85.
7. Migita, T., S. Ruiz, A. Fornari, M. Fiorentino, C. Priolo, G. Zadra, F. Inazuka, C. Grisanzio, E. Palescandolo, E. Shin, et al. 2009. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J. Natl. Cancer Inst. 101 : 519-532.
8. Knowles, L. M., C. Yang, A. Osterman, and J. W. Smith. 2008. Inhibition of fatty-acid synthase induces caspase-8-mediated tumor cell apoptosis by up-regulating DDIT4. J. Biol. Chem. 283 : 31378-31384.
9. Kuhajda, F. P., S. Piantadosi, and G. R. Pasternack. 1989. Haptoglobinrelated protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. N. Engl. J. Med. 321 : 636-641.
10. Kuhajda, F. P., K. Jenner, F. D. Wood, R. A. Hennigar, L. B. Jacobs, J. D. Dick, and G. R. Pasternack. 1994. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc. Natl. Acad. Sci. USA. 91 : 6379-6383.
11. Alò, P. L., P. Visca, A. Marci, A. Mangoni, C. Botti, and U. Di Tondo. 1996. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer. 77 : 474-482.
12. Alò, P. L., P. Visca, G. Trombetta, A. Mangoni, L. Lenti, S. Monaco, C. Botti, D. E. Serpieri, and U. Di Tondo. 1999. Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas. Tumori. 85 : 35-40.
13. Shurbaji, M. S., J. H. Kalbfl eisch, and T. S. Thurmond. 1996. Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum. Pathol. 27 : 917-921.
14. Liu, H., Y. Liu, and J. T. Zhang. 2008. A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpressionmediated palmitate overproduction. Mol. Cancer Ther. 7 : 263-270.
15. Yang, Y., H. Liu, Z. Li, Z. Zhao, M. Yip-Schneider, Q. Fan, C. M. Schmidt, E. G. Chiorean, J. Xie, L. Cheng, et al. 2011. Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers. Int. J. Biochem. Mol. Biol. 2 : 89-98.
16. Dong, Z., Y. Liu, and J. T. Zhang. 2005. Regulation of ribonucleotide reductase M2 expression by the upstream AUGs. Nucleic Acids Res. 33 : 2715-2725.
17. Wu, B. X., C. J. Clarke, and Y. A. Hannun. 2010. Mammalian neutral sphingomyelinases: regulation and roles in cell signaling responses. Neuromolecular Med. 12 : 320-330.
18. Clarke, C. J., E. A. Cloessner, P. L. Roddy, and Y. A. Hannun. 2011. Neutral sphingomyelinase 2 (nSMase2) is the primary neutral sphingomyelinase isoform activated by tumour necrosis factor-alpha in MCF-7 cells. Biochem. J. 435 : 381-390.
19. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purifi cation. Can. J. Biochem. Physiol. 37 : 911-917.
20. Cogolludo, A., L. Moreno, G. Frazziano, J. Moral-Sanz, C. Menendez, J. Castaneda, C. Gonzalez, E. Villamor, and F. Perez-Vizcaino. 2009. Activation of neutral sphingomyelinase is involved in acute hypoxic pulmonary vasoconstriction. Cardiovasc. Res. 82 : 296-302.
21. Lazebnik, Y. A., S. H. Kaufmann, S. Desnoyers, G. G. Poirier, and W. C. Earnshaw. 1994. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature. 371 : 346-347.
22. Han, B., H. Xie, Q. Chen, and J. T. Zhang. 2006. Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3sigma. Mol. Cancer Ther. 5 : 903-912.
23. Kelly, M. M., B. D. Hoel, and C. Voelkel-Johnson. 2002. Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol. Ther. 1 : 520-527.
24. El-Zawahry, A., J. McKillop, and C. Voelkel-Johnson. 2005. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer. 5 : 2.
25. Castaneda, C. A., H. Cortes-Funes, H. L. Gomez, and E. M. Ciruelos. 2010. The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer. Cancer Metastasis Rev. 29 : 751-759.
26. Li, X., Y. Lu, K. Liang, B. Liu, and Z. Fan. 2005. Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells. Breast Cancer Res. 7 : R589-R597.
27. Panner, A., C. A. Crane, C. Weng, A. Feletti, A. T. Parsa, and R. O. Pieper. 2009. A novel PTEN-dependent link to ubiquitination controls FLIPS stability and TRAIL sensitivity in glioblastoma multiforme. Cancer Res. 69 : 7911-7916.
28. Panner, A., C. A. Crane, C. Weng, A. Feletti, S. Fang, A. T. Parsa, and R. O. Pieper. 2010. Ubiquitin-specifi c protease 8 links the PTEN-Akt-AIP4 pathway to the control of FLIPS stability and TRAIL sensitivity in glioblastoma multiforme. Cancer Res. 70 : 5046-5053.
29. Senchenkov, A., D. A. Litvak, and M. C. Cabot. 2001. Targeting ceramide metabolism-a strategy for overcoming drug resistance. J. Natl. Cancer Inst. 93 : 347-357.
30. Ito, H., M. Murakami, A. Furuhata, S. Gao, K. Yoshida, S. Sobue, K. Hagiwara, A. Takagi, T. Kojima, M. Suzuki, et al. 2009. Transcriptional regulation of neutral sphingomyelinase 2 gene expression of a human breast cancer cell line, MCF-7, induced by the anti-cancer drug, daunorubicin. Biochim. Biophys. Acta. 1789 : 681-690.
31. Hanahan, D., and R. A. Weinberg. 2011. Hallmarks of cancer: the next generation. Cell. 144 : 646-674.
32. Menendez, J. A., R. Lupu, and R. Colomer. 2004. Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER-2/neu-overexpressing human breast cancer cells to docetaxel (taxotere). Breast Cancer Res. Treat. 84 : 183-195.
33. Menendez, J. A., R. Colomer, and R. Lupu. 2004. Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells. Oncol. Rep. 12 : 411-422.
34. Menendez, J. A., L. Vellon, R. Colomer, and R. Lupu. 2005. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. Int. J. Cancer. 115 : 19-35.
35. Knowles, L. M., and J. W. Smith. 2007. Genome-wide changes accompanying knockdown of fatty acid synthase in breast cancer. BMC Genomics. 8 : 168.
36. Hoffmann, E., O. Dittrich-Breiholz, H. Holtmann, and M. Kracht. 2002. Multiple control of interleukin-8 gene expression. J. Leukoc. Biol. 72 : 847-855.
37. Marchesini, N., C. Luberto, and Y. A. Hannun. 2003. Biochemical properties of mammalian neutral sphingomyelinase2 and its role in sphingolipid metabolism. J. Biol. Chem. 278 : 13775-13783.
38. Luberto, C., D. F. Hassler, P. Signorelli, Y. Okamoto, H. Sawai, E. Boros, D. J. Hazen-Martin, L. M. Obeid, Y. A. Hannun, and G. K. Smith. 2002. Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. J. Biol. Chem. 277 : 41128-41139.
39. Nemoto, S., M. Nakamura, Y. Osawa, S. Kono, Y. Itoh, Y. Okano, T. Murate, A. Hara, H. Ueda, Y. Nozawa, et al. 2009. Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation. J. Biol. Chem. 284 : 10422-10432.
40. Jaffrézou, J. P., T. Levade, A. Bettaieb, N. Andrieu, C. Bezombes, N. Maestre, S. Vermeersch, A. Rousse, and G. Laurent. 1996. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J. 15 : 2417-2424.
41. Clarke, C. J., T. G. Truong, and Y. A. Hannun. 2007. Role for neutral sphingomyelinase-2 in tumor necrosis factor alpha-stimulated expression of vascular cell adhesion molecule-1 (VCAM) and intercellular adhesion molecule-1 (ICAM) in lung epithelial cells: p38 MAPK is an upstream regulator of nSMase2. J. Biol. Chem. 282 : 1384-1396.
42. De Palma, C., E. Meacci, C. Perrotta, P. Bruni, and E. Clementi. 2006. Endothelial nitric oxide synthase activation by tumor necrosis factor alpha through neutral sphingomyelinase 2, sphingosine kinase 1, and sphingosine 1 phosphate receptors: a novel pathway relevant to the pathophysiology of endothelium. Arterioscler. Thromb. Vasc. Biol. 26 : 99-105.
43. Wheeler, D., E. Knapp, V. V. Bandaru, Y. Wang, D. Knorr, C. Poirier, M. P. Mattson, J. D. Geiger, and N. J. Haughey. 2009. Tumor necrosis factor-alpha-induced neutral sphingomyelinase-2 modulates synaptic plasticity by controlling the membrane insertion of NMDA receptors. J. Neurochem. 109 : 1237-1249.
44. Tangpong, J., M. P. Cole, R. Sultana, G. Joshi, S. Estus, M. Vore, W. St Clair, S. Ratanachaiyavong, D. K. St Clair, and D. A. Butterfi eld. 2006. Adriamycin-induced, TNF-alpha-mediated central nervous system toxicity. Neurobiol. Dis. 23 : 127-139.
45. Lin, C. F., C. L. Chen, W. T. Chang, M. S. Jan, L. J. Hsu, R. H. Wu, M. J. Tang, W. C. Chang, and Y. S. Lin. 2004. Sequential caspase-2 and caspase-8 activation upstream of mitochondria during ceramideand etoposide-induced apoptosis. J. Biol. Chem. 279 : 40755-40761.